⏳ Fetching live dividend data...
Home › Calculator › VACC Dividend Calculator 2026
Vaccitech plc · NASDAQ
Price: $5.00 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in VACC → $237817049.57M in 10 years · $19,769,821,298,702.93/month
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime.
Ready to invest? Open VACC position with:
Real after-tax yield depends on where you live and how you hold VACC.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 40.00% | 37.20% | $4,000 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 34.00% | 31.20% | $3,400 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 32.00% | 29.20% | $3,200 / yr |
| 🇬🇧 UK ISA | 0% | 40.00% | 37.20% | $4,000 / yr |
| 🇬🇧 UK Taxable | 8.75% | 36.50% | 33.70% | $3,650 / yr |
| 🇨🇦 TFSA | 0% | 40.00% | 37.20% | $4,000 / yr |
| 🇨🇦 CA Taxable | 25% | 30.00% | 27.20% | $3,000 / yr |
| 🇦🇺 Super (pension) | 15% | 34.00% | 31.20% | $3,400 / yr |
| 🇦🇺 AU Taxable | 30% | 28.00% | 25.20% | $2,800 / yr |
| 🇩🇪 DE Taxable | 26.375% | 29.45% | 26.65% | $2,945 / yr |
| 🇫🇷 FR Taxable | 30% | 28.00% | 25.20% | $2,800 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
VACC pays quarterly — 4 times per year. Next ex-div: TBD.
How VACC compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for VACC sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2024-01-02 | 105,000 | $3.70 | $388.5K | ||
| A-Award | 2024-01-02 | 96,500 | $3.70 | $357.1K | ||
| A-Award | 2024-01-02 | 443,981 | $3.70 | $1.64M | ||
| A-Award | 2024-01-02 | 193,000 | $3.70 | $714.1K | ||
| Buy | 2023-06-26 | 10,000 | $2.44 | $24.4K | ||
| Buy | 2023-05-25 | 13,750 | $2.66 | $36.6K | ||
| A-Award | 2023-05-11 | 19,197 | $2.27 | $43.6K | ||
| A-Award | 2023-05-11 | 19,197 | $2.27 | $43.6K | ||
| A-Award | 2023-05-11 | 19,197 | $2.27 | $43.6K | ||
| A-Award | 2023-05-11 | 19,197 | $2.27 | $43.6K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the VACC dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →